675596-31-3

Usage

Uses

Used in Organic Synthesis:
2'-Trifluoromethyl-biphenyl-3-carbaldehyde is used as a building block in organic synthesis for its unique chemical properties. The trifluoromethyl group contributes to the reactivity and stability of the compound, making it a versatile component in the creation of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 2'-trifluoromethyl-biphenyl-3-carbaldehyde serves as a key intermediate. Its properties and versatility are harnessed in the development of new drugs, where it can be incorporated into the molecular structures of potential therapeutic agents.
Used as a Precursor in the Synthesis of Biologically Active Molecules:
2'-TRIFLUOROMETHYL-BIPHENYL-3-CARBALDEHYDE is also utilized as a precursor in the synthesis of various biologically active molecules. Its role in the creation of such molecules underscores its importance in the pharmaceutical industry, where it contributes to the advancement of drug discovery and the development of novel therapeutics.
Used in Agrochemical Development:
2'-Trifluoromethyl-biphenyl-3-carbaldehyde's unique properties also make it valuable in the field of agrochemicals. It can be used to develop new pesticides or other agrochemicals that may offer improved efficacy or reduced environmental impact compared to existing products.

Upstream product

• 392-83-6 o-trifluoromethylphenyl bromide 
• 87199-16-4 3-Formylphenylboronic acid 
• 3132-99-8 m-bromobenzoic aldehyde 
• 1423-27-4 2-(trifluoromethyl)phenylboronic acid 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold

Based on an old phenoxyacetic acid scaffold, CPU014 (compound 14) has been identified as a superior agonist by comprehensive exploration of structure-activity relationship. In vitro toxicity study suggested that CPU014 has lower risk of hepatotoxicity than TAK-875. During acute toxicity study (5–500 mg/kg), a favorable therapeutic window of CPU014 was observed by evaluation of plasma profiles and liver slices. Moreover, CPU014 promotes insulin secretion in a glucose-dependent manner, while no GLP-1 secretion has been enhanced. Other than good pharmacokinetic properties, CPU014 significantly improved glucose tolerance both in normal and diabetic models without the risk of hypoglycemia. These subversive findings provided a safer candidate CPU014, which is currently in preclinical study to assess its potential for the treatment of diabetes.

Discovery of phenylsulfonyl acetic acid derivatives with improved efficacy and safety as potent free fatty acid receptor 1 agonists for the treatment of type 2 diabetes

The free fatty acid receptor 1 (FFA1) has emerged as an attractive anti-diabetic target that mediates glucose-stimulated insulin secretion. Several FFA1 agonists have been reported, but many of them possessed somewhat high lipophilicity and/or molecular weight. Herein, we describe the identification of sulfone-carboxylic acid moiety with the multiple advantages of reducing lipophilicity, cytotoxicity and β-oxidation associated with compound 2. Further structure-activity relationship study based on the previleged scaffolds led to the discovery of 2-{(4-[(2’-chloro-[1,1’-biphenyl]-3-yl)methoxy]phenyl)sulfonyl}acetic acid (compound 20), which showed a better balance than compound 2 in terms of physicochemical properties, cytotoxicity profiles and pharmacokinetic properties. Subsequent in vivo studies demonstrated that compound 20 robustly improves the glucose tolerance both in normal and type 2 diabetic models without the risk of hypoglycemia. Compared to the high risk of TAK-875 induced liver toxicity, there was no significant adverse effects such as hepatic and renal toxicity were observed in the chronic toxicity studies of compound 20 even at the higher dose.

Discovery and structure-activity relationships of pyrrolone antimalarials

In the pursuit of new antimalarial leads, a phenotypic screening of various commercially sourced compound libraries was undertaken by the World Health Organisation Programme for Research and Training in Tropical Diseases (WHO-TDR). We report here the detailed characterization of one of the hits from this process, TDR32750 (8a), which showed potent activity against Plasmodium falciparum K1 (EC50 ～ 9 nM), good selectivity (>2000-fold) compared to a mammalian cell line (L6), and significant activity against a rodent model of malaria when administered intraperitoneally. Structure-activity relationship studies have indicated ways in which the molecule could be optimized. This compound represents an exciting start point for a drug discovery program for the development of a novel antimalarial.